Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.61 |
| ▸ | TNKS | O95271 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | SOAT1 | P35610 | 5/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9514091 | 0.86 | RAB9A (0.74) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL9512664 | 0.85 | RAB9A (0.78) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL5391564 | 0.85 | ALDH1A1 (0.52) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL5391572 | 0.85 | ALDH1A1 (0.52) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL13617010 | 0.85 | RAB9A (0.73) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL9513272 | 0.84 | RAB9A (0.76) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL1704979 | 0.83 | RAB9A (0.74) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL9514685 | 0.82 | RAB9A (1.00) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| Hydrochloric Acid SCHEMBL1704951 | 0.82 | RAB9A (0.73) | RAB9AGRIN2AGRIN2BTNKSPARP1 | |
| SCHEMBL5387405 | 0.82 | ALDH1A1 (0.57) | RAB9AGRIN2AGRIN2BTNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1460065-B1 | PROCESSES FOR PRODUCTION OF CYCLIC DIAMINE COMPOUNDS OR SALTS THEREOF | KOWA CO (JP) | 2012-12-05 | — | — | EP | claimed |
| EP-1566381-B1 | PROCESS FOR PRODUCTION OF 1- 2-(BENZIMIDAZOL-2-YL- THIO)ETHYL PIPERAZINE OR SALTS THEREOF | KOWA CO (JP) | 2009-11-11 | — | — | EP | claimed |
| US-7214796-B2 | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | KOWA CO., LTD. (JP) | 2007-05-08 | — | — | US | claimed |
| US-20060035906-A1 | Process for production of 1-[2-(benzimidazol-2-yl- thio)ethy]piperazine or salts thereof | KOWA CO., LTD. AICHI, JAPAN | 2006-02-16 | — | — | US | claimed |
| US-6998486-B2 | Process for production of cyclic diamine compounds or salts thereof | KOWA CO., LTD. (JP) | 2006-02-14 | — | — | US | claimed |
| EP-1566381-A1 | PROCESS FOR PRODUCTION OF 1- 2-(BENZIMIDAZOL-2-YL- THIO)ETHYL ]PIPERAZINE OR SALTS THEREOF | Kowa Co., Ltd. (JP) | 2005-08-24 | — | — | EP | claimed |
| US-20050032814-A1 | Process for production of cyclic diamine compounds or salts thereof | KOWA CO., LTD. (JP) | 2005-02-10 | — | — | US | claimed |
| EP-1460065-A1 | PROCESSES FOR PRODUCTION OF CYCLIC DIAMINE COMPOUNDS OR SALTS THEREOF | Kowa Co., Ltd. (JP) | 2004-09-22 | — | — | EP | claimed |
| EP-1460065-B1 | PROCESSES FOR PRODUCTION OF CYCLIC DIAMINE COMPOUNDS OR SALTS THEREOF | KOWA CO (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-1566381-B1 | PROCESS FOR PRODUCTION OF 1- 2-(BENZIMIDAZOL-2-YL- THIO)ETHYL PIPERAZINE OR SALTS THEREOF | KOWA CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7214796-B2 | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | KOWA CO., LTD. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-7214796-B2 | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | KOWA CO., LTD. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20060035906-A1 | Process for production of 1-[2-(benzimidazol-2-yl- thio)ethy]piperazine or salts thereof | KOWA CO., LTD. AICHI, JAPAN | 2006-02-16 | — | — | US | disclosed |
| US-6998486-B2 | Process for production of cyclic diamine compounds or salts thereof | KOWA CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| EP-1566381-A1 | PROCESS FOR PRODUCTION OF 1- 2-(BENZIMIDAZOL-2-YL- THIO)ETHYL ]PIPERAZINE OR SALTS THEREOF | Kowa Co., Ltd. (JP) | 2005-08-24 | — | — | EP | disclosed |
| US-20050032814-A1 | Process for production of cyclic diamine compounds or salts thereof | KOWA CO., LTD. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1460065-A1 | PROCESSES FOR PRODUCTION OF CYCLIC DIAMINE COMPOUNDS OR SALTS THEREOF | Kowa Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035906-A1 | Process for production of 1-[2-(benzimidazol-2-yl- thio)ethy]piperazine or salts thereof | SAT1, ACAT2, NAT1 | RAB9A 2124/4885GRIN2A 3351/4885GRIN2B 3885/4885 |
| US-20050032814-A1 | Process for production of cyclic diamine compounds or salts thereof | SRM, DDC, QDPR | RAB9A 2190/4885GRIN2A 2702/4885GRIN2B 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.